Merck scores US, German wins over Halozyme in Keytruda Qlex patent fight

Law Legal System Justice Crime concept. Mallet Gavel Hammer and Scales on tabl
The Patent Trial and Appeal Board ruled that all challenged claims in two post-grant reviews filed by Merck against Halozyme are unpatentable, bringing Merck's winning streak to 14. (iStock / Getty Images Plus)

Merck & Co. has delivered a one-two legal punch against Halozyme Therapeutics, clearing major commercialization hurdles for subcutaneous Keytruda just as the New Jersey pharma works to defend its flagship cancer franchise.

In two post-grant review decisions handed out Wednesday, the U.S. Patent Trial and Appeal Board (PTAB) sided with Merck, ruling that claims in a pair of Halozyme patents related to Merck’s Keytruda Qlex are invalid. 

The rulings round out Merck’s winning streak: of 15 post-grant review challenges that Merck brought against Halozyme, the Big Pharma company won all 14 that were granted a review. 

The dispute centers on Halozyme’s Mdase group of patents around modified hyaluronidase enzymes that can enable subcutaneous drug delivery. Halozyme argues that the berahyaluronidase alfa (ALT-B4) developed by South Korea’s Alteogen and used in Keytruda Qlex infringes on its Mdase.

The patent battle carries major commercial weight. Merck has been counting on the under-the-skin version to cushion the blow to Keytruda as the original intravenous product nears patent expirations. In the third quarter, Keytruda Qlex’s sales mounted to $830 million, following its U.S. launch in late September 2025.

Across the Atlantic, Merck scored another boost as a court in Germany overturned a preliminary injunction that had blocked the company from launching subcutaneous Keytruda in the country since December 2025. Lifting the preliminary ban opens the door for Merck to bring the newer injection to one of Europe’s largest markets.

While those decisions represent positive developments for Merck, Halozyme hasn’t completely lost its cause on either continent yet. 

In a Nov. 19 statement, Halozyme’s chief legal officer Mark Snyder said the San Diego biotech disagrees with the German court’s decision and “will immediately file an infringement lawsuit against Merck in Germany seeking permanent relief.”

Halozyme also still holds a separate October 2026 victory in the form of a preliminary injunction from a Dutch court that barred subcutaneous Keytruda across eight European markets, including the Netherlands, France, Belgium, Denmark, Ireland, Italy, Sweden and Switzerland.

Back in the U.S., the PTAB rulings remain subject to appeal. According to the U.S. Patent and Trademark Office’s database, six of Merck’s post-grant review challenges are marked “pending director review” following their initial verdict in favor of the Keytruda maker. 

What’s more, Halozyme has a patent infringement lawsuit in the U.S. District Court for the District of New Jersey, which is being paused pending the PTAB results. 

Nevertheless, Merck seems undeterred. During the company’s third-quarter earnings call, CEO Rob Davis described the injunction in Europe as a procedural step before a hearing is held, and that it “doesn’t speak to the merits of our belief.”

“Overall, I just want to emphasize, we feel very strongly that we have IP that gives us freedom to operate as it relates to Qlex,” Davis said, later adding that “nothing has changed to our confidence we see long term.”

Merck and Halozyme did not respond to Fierce's inquiries for this story.